The role of inflammation in kidney cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 197-234

  De Vivar Chevez, Antonio Roma ^a   Finke, James ^a   Bukowski, Ronald ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; EVEROLIMUS; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PAZOPANIB; PHOSPHOGLYCERATE KINASE; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR; VINBLASTINE; VON HIPPEL LINDAU PROTEIN; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE 14; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CLEAR CELL CARCINOMA; CYTOKINE STORM; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY SURGERY; LIVER TOXICITY; LUNG TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; NEPHRECTOMY; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SUPPRESSOR CELL; SURVIVAL TIME; TUMOR ESCAPE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ADVANCED CANCER; ANTIINFLAMMATORY ACTIVITY; BONE MARROW CELL; BRAIN TOXICITY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL TOXICITY; GENE FUNCTION; METASTASIS POTENTIAL; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TRANSPORT; SURVIVAL RATE; TH1 CELL; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84934438318     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_9     Document Type: Article

References (223)

1. Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Mov assagh M, Lu W, Mills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR (2010) Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 177:943-954
2. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50:409-418
3. American Cancer Society (2008) Cancer facts and figures. American Cancer Society, New York
4. Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP (1999) Transforming growth factor be ta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59:2210-2216
5. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40
6. Aoki Y Feldman GM Tosato G 2003 Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma Blood 101: 1535-1542
7. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540-550
8. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99:881-889
9. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show eff icacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616
10. Begum NA, Shibuta K, Mori M, Barnard GF (1999) Reduced expression of the CXCR4 receptor mRNA in hepatocellular carcinoma and lack of inducibility of its ligand alpha-chemokine hIRH/SDF1alpha/PBSF in vitro. Int J Oncol 14:927-934
11. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A , Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759
12. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896
13. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF et al (1992 ) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317-3322
14. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129:2158-2170
15. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98:7319-7324
16. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S , Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng l J Med 366:2455-2465
17. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, Lang S (2011) Myeloid-derived suppressor cells in t he peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311-317
18. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW (2002) Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99:53-57
19. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945-954
20. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
21. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to a poptosis in human U266 myeloma cells. Immunity 10:105-115
22. Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K (2004a ) Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol 172:2153-2157
23. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T (2004b ) Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108:825-832
24. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prog nostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-624
25. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379-385
26. Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, Choueiri TK (2011) Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 171:1487-1493
27. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated wit h vascular endothelial growth factortargeted therapy. Cancer 110:543-550
28. Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH (2008) Tumorderived tumor necrosis factor-alph a promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 99:905-913
29. Clement JM, McDermott DF (2009) The high-dose aldesleukin (IL-2) " select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 7:E7-E9
30. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477-2490
31. Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Ray man PA, Rini BI, Gendler SJ, Finke JH (2012) Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Inv est 41:680-710
32. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425 1-87
33. Corzo C A, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor ce lls. J Immunol 182:5693-5701
34. D'Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P, Carteni G, Mirone V, Longo N, Marra L, Pe rdona S, Claudio L, Mascolo M, Staibano S, Falsaperla M, Puglisi M, Martignoni G, Ficarra V, Castello G, Scala S (2010a) Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 9:4 492-4500
35. D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdona S, Pignata S, Facchini G, Carteni G, Longo N, Pucci L , Ottaiano A, Costantini S, Castello G, Scala S (2010b) Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 10:772-781
36. Dale KM, Coleman CI, H enyan NN, Kluger J, White CM (2006) Statins and cancer risk: a metaanalysis. JAMA 295:74-80
37. Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, Rosser CJ, Su LM, Vieweg J, Kusmartsev S (2011) Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 71:6400-6409
38. Dekernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:148-152
39. Devita VT, Lawrence TS, Rosenberg SA (2011) DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
40. Dillman RO, Barth NM, Vandermolen LA, Fong WH, Mahdavi KK, McClure SE (2011) Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm 26:273-277
41. Do nskov F (2013) Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 23:200-207
42. Donskov F, von der Maase H (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997-2005
43. Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard F, Cabane J (1994) Tumour necrosis factor-alpha, interleukin-1 be ta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30A:162-167
44. Du W, Wright BM, Li X, Finke J, Rini BI, Zhou M, He H, Lal P, Welford SM (2013) Tumorderived macrophage mi gration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene 32:1469-1474
45. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine i n tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
46. Edgren M, Lennernas B, Larsson A, Nilsson S (1999) Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 19:869-873
47. Elsasser-Beile U, Rindsfuser M, Grussenmeyer T, Schultze-Seemann W, Wetterauer U (2000) Enhanced expression of IFN-gamma mRNA in CD 4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. Br J Cancer 83:637-641
48. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johns on RS, Arbeit JM (2001) Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 15:2520-2532
49. Escudier B (2010) Chemo-immun otherapy in RCC: the end of a story. Lancet 375:613-614
50. Esteban MA Harten SK Tran MG Maxwell PH 2006) Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor s uppressor protein J Am Soc Nephrol 17: 1801-1806
51. Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, Liu Z (2013) Simvastatin inhibits renal cancer cell g rowth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS ONE 8:e62823
52. Farsaci B, Higgins JP, Hodge JW (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130:1948-1959
53. Farwell WR, Scranto n RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139
54. Finke JH, Rini B , Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma pati ents. Clin Cancer Res 14:6674-6682
55. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, Deconti R, Antonia S, Gabrilovich D, Fishman M (2010) Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 33:817-827
56. Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, Denapoli T, Parekh DJ, Gorin Y, Block K (2012) Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6-and 8-production. PLoS ONE 7:e30712
57. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic ren al-cell cancer. N Engl J Med 345:1655-1659
58. Fortis C, Ferrero E, Biffi M, Heltai S, Besana C, Bucci E, Tresoldi M, Rugarli C (1991) Recombinant interleukin-2 and lymphokine-activated kille r cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation. Cancer Immunol Immunother 33:128-132
59. Francis RB Jr, Thomas W (1984) Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemost 52:71-74
60. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Ok azaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to nega tive regulation of lymphocyte activation. J Exp Med 192:1027-1034
61. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ (2011) Generation of a mouse model of von Hippel-Lindau kidney disease leading to renal can cers by expression of a constitutively active mutant of HIF1alpha. Cancer Res 71:6848-6856
62. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K (2007) Cyclooxygenase-2 (COX-2) in carcinogenesis and sele ctive COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 38:78-82
63. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941-952
64. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253-268
65. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, Lopez-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17:372-385
66. Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, Murphy PM, Luster AD (1996a ) Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and-3. J I mmunol 157:5613-5626
67. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD (1996b ) Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 2:449-456
68. Gauthaman K, Fong CY, Bongso A (2009) Statins, stem cells, and cancer. J Cell Biochem 106:975-983
69. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27:291-301
70. Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH (2001) Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic ph enotype. Cancer Res 61:6255-6263
71. Haase VH Glickman JN Socolovsky M Jaenisch R 2001) Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor Proc Natl Acad Sci USA 98: 1583-1588
72. Halama N, Zoernig I, Jaeger D (2010) Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol 2010:689893
73. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 183:937-944
74. Heeschen C, Aicher A, L ehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340-1346
75. Hemmerlein B, Johanns U, Halbfass J, Bottcher T, Heuser M, Radzun HJ, Thelen P (2004) The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide. Int J Oncol 24:1069-1076
76. Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, Sun KH (2012) TNF-alpha induces epithelial-mesenchymal transition of renal cell carcin oma cells via a GSK3beta-dependent mechanism. Mol Cancer Res 10:1109-1119
77. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M (2002) Activation of signal transducer and activator of trans cription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168:762-765
78. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Haya kawa M (2004) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10:8648-8655
79. Howlader NNA, Krapcho M, Garsh ell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975-2010. National Cancer Insti tute (Posted to the SEER web site
80. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Brombe rg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
81. Hua ng D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 7 0:1063-1071
82. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
83. Ikemoto S, Yoshi da N, Narita K, Wada S, Kishimoto T, Sugimura K, Nakatani T (2003) Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 10:1843-1849
84. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-10599
85. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27:4709-4717
86. Jiang W, Zhou P, Kahn SM, Tomita N, Johnson MD, Weinstein IB (1994) Molecular cloning of TPAR1, a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA). Exp Cell Res 215:284-293
87. Joh rer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Holtl L, Bartsch G, Greil R, Thurnher M (2005) Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 11:2459-2465
88. Kaelin WG Jr (2009) Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115:2262-2272
89. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113-3119
90. Kallio JP, Tammela TL, Marttinen AT, Kellokumpu-Lehtinen PL (2001) Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res 20:523-528
91. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG (2011) Development and characterization of clinically relevant tumor models from patients with renal cell ca rcinoma. Eur Urol 59:619-628
92. Khurana V, Caldito G, Ankem M (2008) Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 71:118-122
93. Kleymenova E, Everitt JI, Pluta L, Portis M, Gnarra JR, Walker CL (2004) Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis 2 5:309-315
94. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH (2009) Sunitinib mediates reversal of myeloidderived suppresso r cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148-2157
95. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526-3536
96. Koga T, Shibahara K, Kabashima A, Sumiyoshi Y, Kimura Y, Takahashi I, Kakeji Y, Maehara Y (2004) Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer. Hepatogastroenterology 51:1626-1630
97. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M (2011) Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102:1424-1431
98. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osa ka Y, Futatsuyama K, Toma H, Tanabe K (2006) Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97:780-786
99. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160:1914-1918
100. Kujawski M, K ortylewski M, Lee H, Herrmann A, Kay H, Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367-3377
101. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H (2010) Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 70:9599-9610
102. K usmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cance r Res 14:8270-8278
103. Laurell M, Christensson A, Abrahamsson PA, Stenflo J, Lilja H (1992) Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 89:1094-1101
104. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824-832
105. Leahy KM, Ornberg RL, Wang Y, Zweifel B S, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625-631
106. Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE (2009) Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 15:2647-2656
107. Li L, Kaelin WG J r (2011) New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25:667-686
108. Lieberthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20:2493-2502
109. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM , Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL (2013) Durable cancer regression offtreatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19:462-468
110. Liscovsky MV, Ranocchia RP, Alignani DO, Gorlino CV, Moron G, Maletto BA, Pistoresi-Palencia MC (2011) CpG-ODN+IFN-gamma confer pro-and anti-inflammatory properties to peritoneal macrophages in aged m ice. Exp Gerontol 46:462-467
111. Lopez-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS (2013) Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during r enal cell carcinoma progression. Oncogene 32:1752-1760
112. Luo J (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273:194-200
113. Lutz MS, Burk RD (2006) Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res 66:6903-6907
114. Maher ER Neumann HP Richard S (2011) von Hippel-Lindau disease: a clinical and scientific review Eur J Hum Genet 19: 617-623
115. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibe rt K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
116. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A (1992) Transforming growth factor-beta. Cancer Surv 12:81-103
117. McDermott DF, Rini BI (2007) Immunotherapy for metastatic renal cell carcinoma. BJU Int 99:1282-1288
118. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, S h irazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokin etic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
119. Menke J, Iwata Y, Rabacal WA, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR (2009) CSF-1 sign als directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 119:2330-2342
120. Menke J, Kriegsmann J, Schimanski CC, Schwartz MM, Schwarting A, Kelley VR (2012) Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res 72:187-200
121. Michaelson MD, Stadler WM (2013) Predictive markers in advanced renal cell carcinoma. Semin Oncol 40:459-464
122. Middleton AW Jr (1980) Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol Clin North Am 7:711-717
123. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299-9307
124. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schroder JM (1998) IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection an d atopy. J Immunol 160:60-68
125. Morandi A, Barbetti V, Riverso M, Sbarba PD, Rovida E (2011) The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer c ell lines. PLoS ONE 6:e27450
126. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969
127. Motzer RJ, Hutson TE, Tomczak P , Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N En gl J Med 356:115-124
128. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
129. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell car cinoma. J Clin Oncol 18:2972-2980
130. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, Deprimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006a ) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
131. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006b ) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524
132. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
133. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI (2010) Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune respon se in cancer. Clin Cancer Res 16:1812-1823
134. Najjar YG, Finke JH (2013) Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 3:49
135. Negr ier S Escudier B Gomez F Douillard JY Ravaud A Chevreau C Buclon M Perol D Lasset C 2002 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cy tokines: a report from the Groupe Francais d'Immunotherapie Ann Oncol1 13: 1460-1468
136. Neidhart JA (1986) Interferon therapy for the treatment of renal cancer. Cancer 57:1696-1699
137. Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O, Kojima Y (2013) Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. Eur J Cancer 49:1715-1724
138. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin B J, Kley N, Kaelin WG Jr, Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968
139. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin T (2001) The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 276:43 611-43617
140. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28:143-149
141. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M (2001) Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20:3888-3896
142. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment fo r immune-based cancer therapies. Cancer Res 69:2514-2522
143. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM, Chen SH (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70:99-108
144. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267
145. Pardoll D M (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264
146. Pause A, Lee S, Lonergan KM, Klausner RD (1998) The von Hippel-Lindau tumor suppressor gene is require d for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95:993-998
147. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T ce ll compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-1725
148. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) M yeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238-244
149. Petrella BL, Brinckerhoff CE (2006) Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer 5:66
150. Petrella BL, Lohi J, Brinckerhoff CE (2005) Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24:1043-1052
151. Qi H, Ohh M (2003) The von Hippel-Lindau tumor suppressor protei n sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factorkappaB-dependent antiapoptotic pathway. Cancer Res 63:7076-7080
152. Ramp U, Caliskan E, Mahotka C, Krieg A, Heikaus S, Gabbert HE, Gerharz CD (2003) Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cance r 88:1800-1807
153. Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD (1997) Acquisition of TGFbeta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Inves t 76:739-749
154. Rankin EB, Tomaszewski JE, Haase VH (2006) Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66:2576-2583
155. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with cel ecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62:165-170
156. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686
157. Rempel SA, Dudas S, Ge S, Gutierrez JA (2000) I dentification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6:102-111
158. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603-1616
159. Rini BI, Campbell SC (2009) Renal cell carcinoma. People's Medical Pub. House, McGraw Hill Education, Shelton
160. Maidenhead Rini BI, Weinberg V, Small EJ (2005) A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 103:553-558
161. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:566-575
162. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177:346-352
163. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553-1560
164. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22:395-405
165. Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F (2006) Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary t umors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 68:303-310
166. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149-163
167. Saito K, Kihara K (2013) Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 20:161-171
168. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145-1153 Sassano A, Platanias LC (2008) Statins in tumor suppression. Cancer Lett 260:11-19
169. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M (1999) Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor gr owth in vivo. Lab Invest 79:1469-1477
170. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer pa tients. Cancer Res 61:4756-4760
171. Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18-II26
172. Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, Atzpodien J, Buer J, Lauber J (2002) CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86:1250-1256
173. Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI (2011) Clinical and immunomodulatory effects of celecoxib plus interferonalpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol 31:690-698
174. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP (1998) C XCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 69:99-104
175. Seiki M, Yana I (2003) Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 94:569-574
176. Shibuta K, Begum NA, Mori M, Shimoda K, Akiyoshi T, Barnard GF (1997) Reduced expression of the CXC chemokine hI RH/SDF-1alpha mRNA in hepatoma and digestive tract cancer. Int J Cancer 73:656-662
177. Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592-1599
178. Shrikant P, Khoruts A, Mescher MF (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell-and IL-2-dependent mechanism. Immunity 11:483-493
179. Sica A Bronte V 2007 Altered macrophage differentiation and immune dysfunction in tumor development J Clin Invest 117: 1155-1166
180. Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-Demasters BK, Waziri A (2011) Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting ar ginase I. Clin Cancer Res 17:6992-7002
181. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, Massfelder T (2006) The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66:5130-5142
182. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010) Myeloidderived suppressor ce lls inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68-77
183. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ (2006) A phase II s tudy of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 107:1273-1279
184. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311
185. Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, N ikaido T, Ito H, Ishikura H (2005) Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFNgamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 103:258-267
186. Swiercz R, Wolfe JD, Zaher A, Jankun J (1998) Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Re s 4:869-877
187. Tang PA, Heng DY (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 15:98-104
188. Tavani A, Scotti L, Bosett i C, Dal Maso L, Montella M, Ramazzotti V, Negri E, Franceschi S, La Vecchia C (2010) Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev 19:272-274
189. Thiery JP (2002) Epith elial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
190. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:1 7174-17179
191. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED (2006) Tumor B7-H1 i s associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381-3385
192. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13:1757-1761
193. Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM (2014) Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic p otential. Urol Oncol 32:43.e23-43.e30
194. Tomita S, Ishibashi K, Hashimoto K, Sugino T, Yanagida T, Kushida N, Shishido K, Aikawa K, Sato Y, Suzutani T, Yamaguchi O (2011) Suppressio n of SOCS3 increases susceptibility of renal cell carcinoma to interferon-alpha. Cancer Sci 102:57-63
195. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S , McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
196. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15:381-384
197. Ueno T, Fukuda N, Tsunemi A, Yao EH, Matsuda H, Tahira K, Matsumoto T, Matsumoto K, Matsumoto Y, Nagase H, Sugiyama H, Sawamura T (2009) A novel gene silencer, pyrroleimidazole polyamide targeting human lectin-like oxidized low-density lipoprotein receptor-1 gene improves endothelial cell function. J Hypertens 27:508-516
198. Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schofer C, Zechmeister-Machhart M, Kronke G, Vales A, Carmeliet P, Binder BR, Geiger M (2000) Disruption of the protein C inhibitor gene results in impair ed spermatogenesis and male infertility. J Clin Invest 106:1531-1539
199. Van Boxel-Dezaire AH, Rani MR, Stark GR (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361-372
200. van Cruijsen H van der Veldt AA Vroling L Oosterhoff D Broxterman HJ Scheper RJ Giaccone G Haanen JB van den Eertwegh AJ Boven E Hoekman K de Gruijl TD 2008 Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survivalClin Cancer Res 14:5884-5892
201. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45-65
202. Wakita T, Hayashi T, Nishioka J, Tamaru H, Akita N, Asanuma K, Kamada H, Gabazza EC, Ido M, Kawam ura J, Suzuki K (2004) Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. Int J Cancer 108:516-523
203. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254-1261
204. Wang JM, Deng X, Gong W, Su S (1998) Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220:1-17
205. Wang L, Wang Z, Yang B, Yang Q, Wang L, Sun Y (2009) CXCR4 nuclear l ocalization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol Rep 22:1333-1339
206. Wang L, Chen W, Gao L, Yang Q, Liu B, Wu Z, Wang Y, Sun Y (2012a) High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol 10:212
207. Wang L, Huang T, Chen W, Gao X, Zhou T, Wu Z, Sun Y (2012b) Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncol Rep 28:2043-2048
208. Wang R, Guo L, Wang P, Yang W, Lu Y, Huang Z, Tang C (2013) Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 19:115-125
209. Welford SM, Bed ogni B, Gradin K, Poellinger L, Broome Powell M, Giaccia AJ (2006) HIF1alpha delays premature senescence through the activation of MIF. Genes Dev 20:3366-3371
210. Wigginton JM, Komschlies KL, Ba ck TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38-43
211. Ya goda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60
212. Yamakawa M, Liu LX, Belanger AJ, Date T, Kuriyama T, Goldberg MA, C heng SH, Gregory RJ, Jiang C (2004) Expression of angioproteins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am J Physiol Renal Physiol 287:F649-F657
213. Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumorbearing host directly promotes tumor a ngiogenesis. Cancer Cell 6:409-421
214. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA ( 2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830
215. Yoon SO, Park SJ, Yun CH, Chung AS (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128-137
216. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T (2002) Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 86:1396-1400
217. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI (2012 ) Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 91:167-181
218. Zachary I (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375-C1386
219. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Ma her ER (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811
220. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC (2005) Arginase-producing myelo id suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044-3048
221. Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J (1994) Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur J Immunol 24:435-439
222. Zimmermann N, Conkright JJ, Rothenberg ME (1999) CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem 274:12611-12618
223. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, Dekernion JB, Fig lin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559-4566